Alzheimer's Disease Preclinical CRO Solutions for Drug Discovery
Tackle the complex challenges of Alzheimer's Disease with Cyagen's integrated research platform. We combine validated animal models, end-to-end CRO services, and expert-led strategy to accelerate the discovery of new AD therapeutics for scientists worldwide.
An Integrated Approach to AD Research & Its Challenges
Alzheimer's is the world's leading neurodegenerative disease, with a severe epidemiological outlook and vast unmet medical needs. While progress has been made in understanding key pathogenic mechanisms like Aβ plaques, tauopathy, and neuroinflammation, preclinical research still faces critical bottlenecks, including poor clinical translatability of models and a lack of standardized efficacy evaluation criteria.
To address these complex challenges, Cyagen has developed a powerful and integrated research platform.
Our portfolio of specialized animal models, combined with comprehensive in vivo and in vitro services
detailed below, provides the critical tools scientists need to overcome these hurdles and accelerate
their discovery programs.
{{ item.title }}
{{static_tabs[0].title}}
Cyagen offers a comprehensive portfolio of Alzheimer’s disease research models
and services, spanning ready-to-use and custom mouse models, AAV-induced disease modeling, and
disease-relevant cell products. Integrated in vivo, in vitro, and ex vivo capabilities support
mechanistic research, target validation, biomarker analysis, and preclinical therapeutic
evaluation.
Disease-Relevant Induced Alzheimer's Disease Animal Models
| Model Name | Key Mechanism | Application | Action |
|---|---|---|---|
| AAV-induced Alzheimer's Disease (AD) mouse model | Bilateral hippocampal injection of AAV vectors expressing mutant human APP and PSEN1 in C57BL/6J mice. | Alzheimer's Disease |
Relevant Model
| Catalog Number | Name | Base Strain | Research Application | Action |
|---|---|---|---|---|
| {{ value.product_num || "--" }} | {{ value.product_name || "--" }} | {{ value.product_strain || "--" }} |
；
|
+
|
Next Page
Disease-Relevant Cell Lines for AD Research
Cyagen offers gene-edited human iPSC lines and differentiated neural cell models carrying key
Alzheimer’s disease-associated genes and mutations. These disease-relevant cell models support
mechanistic studies, target validation, and in vitro therapeutic evaluation across multiple
aspects of AD pathology.
| Catalog No | Parental cell | Cell line | Genetic Modification | Application | Species |
|---|---|---|---|---|---|
| SY-iKO-00003 | iPSC | KO-iPSC-APOE | APOE knockout | AD | Human |
| SY-iKI-00003 | iPSC | KI-iPSC-NEUROG2 | NEUROG2 knock-in at the AAVS1 locus | AD | Human |
| SY-iKI-00002 | iPSC | KI-iPSC-NEUROG2-PSEN1 ΔE9 | PSEN1 ΔE9 knock-in at the AAVS1 locus | AD | Human |
| SY-iMU-00013 | iPSC | MU-iPSC-APOE4 (p.C130R) | APOE point mutation (p.C130R) | AD | Human |
| SY-iMU-00014 | iPSC | MU-iPSC-APP-Swedish (p.K670N, p.M671L) | APP Swedish mutation (p.K670N, p.M671L) | AD | Human |
| SY-iMU-00021 | iPSC | MU-iPSC-APOE (p.R154S) | APOE point mutation (p.R154S) | AD | Human |
| SY-iMU-00023 | iPSC | MU-iPSC-PSEN1 (p.M146L) | PSEN1 point mutation (p.M146I) | AD | Human |
| SY-iMU-00033 | iPSC | MU-iPSC-APP (p.E693Q) | APP point mutation (p.E693Q) | AD | Human |
| SY-iMU-00020 | iPSC | MU-iPSC-TREM2 (p.R62H) | TREM2 point mutation (p.R62H) | AD | Human |
| SY-iMU-00001 | iPSC | MU-iPSC-TARDBP (p.M337V) | TARDBP point mutation (p.M337V) | ALS/FTD/AD | Human |
| SY-MU-00031 | HT-22 | MU-HT22-App (p.K595N, p.M596L) | App (p.K595N, p.M596L) | AD | Mouse |
| SY-iN-00001 | iPSC | iPSC-NPC (Neural progenitor cells) | — | Neurology | Human |
| SY-iCN-00001 | iPSC | iPSC-CN (Cortical neurons) | — | AD | Human |
| SY-iAS-00001 | iPSC | iPSC-AS (Astrocytes) | — | AD | Human |
| SY-iMG-00001 | iPSC | iPSC-Microglia | — | AD/PD/ALS | Human |
{{static_tabs[1].title}}
Precision Drug Administration
Our team of skilled specialists is highly experienced in precision injection
methodologies tailored for CNS research. We offer a comprehensive array of validated
administration routes to ensure accurate and reliable delivery of your therapeutic
candidates.
- Systemic Delivery: Intravenous (tail vein), Intraperitoneal, Subcutaneous, etc.
- CNS-Targeted Delivery: Stereotactic brain injection, Intrathecal injection, Intraventricular injection, and Intranasal administration.
Featured Technique: Stereotactic Brain Injection
Our stereotactic injection service enables targeted delivery to specific brain
regions critical to AD pathology, such as the hippocampus and cortex, guided by 3D coordinates
and verified through histological imaging.
Case Study: AAV Delivery to the CNS
Agent: AAV9-CMV-EGFP-HGH
Coordinates: -2mm, ±1.8mm, -1.5mm
Titer: 1.98×10¹⁴ vg/mL
Dose: 1×10¹⁰ vg/0.5μL/site
Imaging Time: 4 weeks post-injection
Figure: Precise injection site visualization using
the brain stereotactic
instrument.
Case Study: LPS-Induced Neuroinflammation Model
Agent: Lipopolysaccharide
Coordinates: +4.8mm, ±1.8mm, -8.0mm
Dose: 4μL/site (5 mg/mL)
Observation Time: 2 weeks post-injection
Observation: Rat displaying unidirectional rotational
movement 14
days post-operation.
Figure: Significant behavioral changes observed 2
weeks post-injection.
Neurobehavioral Assessment for AD
We provide a focused suite of behavioral paradigms essential for evaluating the core cognitive
and functional deficits associated with Alzheimer's Disease.
| Behavioral Domain | Recommended Tests for AD Research | Function Tested |
|---|---|---|
| Learning & Memory | Morris Water Maze | Spatial learning and memory |
| Y-Maze | Spatial working memory | |
| Novel Object Recognition | Recognition memory | |
| Fear Conditioning Test | Associative fear memory | |
| Anxiety & Depression-like Behavior | Elevated Plus Maze | Anxiety-like behavior |
| Open Field Test | Locomotor activity and anxiety | Motor Function & Coordination | Rotarod Test | Motor coordination, balance, and ataxia |
| General Well-being | Nest Building | Assessment of well-being and cognitive decline |
{{static_tabs[2].title}}
We offer a focused suite of analytical services to investigate the core
pathological and molecular features of Parkinson's Disease, and to evaluate the efficacy of
your therapeutic candidates.
| Analysis Category | Specific Services | Key Applications & Targets in AD Research |
|---|---|---|
| Pathology & Biomarker Analysis | Histology & Special Stains (H&E, Congo Red) | Visualize general brain morphology and specifically identify dense-core amyloid plaques. |
| Immunohistochemistry (IHC) / Immunofluorescence (IF) | Detect, localize, and quantify key pathological proteins directly in tissue sections (e.g., Aβ, p-Tau, Iba1 for microglia, GFAP for astrocytes). | |
| ELISA & Immunoassays | Accurately quantify levels of soluble/insoluble Aβ40/42, total Tau/p-Tau, and key inflammatory markers (e.g., cytokines) in brain tissue and plasma. | |
| Gene & Protein Expression | Western Blot | Assess changes in protein levels and post-translational modifications (e.g., phosphorylation of Tau) for key biomarkers. |
| RT-PCR & qPCR | Analyze the expression of target genes (e.g., APP, MAPT), inflammatory factors, and synaptic markers to understand mechanistic changes. | |
| Physiological & Biochemical Analysis | Biochemical Panels | Assess the systemic impact of AD and therapeutic interventions by analyzing immune factors, antioxidant status, blood glucose, and lipid profiles. |
| Metabolic Testing (ITT, GTT) | Evaluate metabolic dysregulation, a known comorbidity and potential driver of AD pathology. |
AAV-induced Alzheimer's Disease (AD) mouse model
Model Validation Case Studies
Why Partner with Cyagen?
Comprehensive Model Solutions
Access a portfolio of ready-to-use, validated models and leverage our deep expertise in developing custom models on classic AD backgrounds.
Integrated Efficacy Platform
Utilize our one-stop, standardized services, from in-life behavioral studies to terminal molecular pathology.
Data-Driven Decision Support
Rely on our stringent quality control and commitment to reproducibility to deliver reliable data that supports your critical project decisions.
Expert-Led Study Design
Collaborate with our team of senior scientists to receive end-to-end support, from model selection to customized experimental protocol design.
Related Resources
Events & Webinars
Special Event MaRS Center 2026
View Details
Promotional Campaign
Shared-Access 300: Fast-Track KO Program
View Details
Blogs & Insights
Is INHBE Only Half of the Activin Story?
View Details
Resource Vault
HUGO-GT™ Models：Efficacy Data & Core Advantages for Small Nucleic Acid Drug Therapeutics
View Details
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
